Istodax is indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Celgene said that sNDA filing for Istodax was supported by the safety and efficacy results of a Phase II, multicenter, international, open-label study of Istodax in progressive or relapsed PTCL following prior systemic therapy.
Istodax is not approved as a treatment in progressive or relapsed PTCL.